edatrexate
Term · Oncology and biomedicine · MLC-T-ONC-002674
An anticancer drug that belongs to a family of drugs called antimetabolites.
A polyglutamatable folate antagonist analogue of methotrexate with antineoplastic activity. Edatrexate inhibits dihydrofolate reductase, thereby increasing cellular levels of polyglutamates, inhibiting thymidylate synthase and glycinamide ribonucleotide formyl transferase, impairing synthesis of purine nucleotides and amino acids, and resulting in tumor cell death. Edatrexate may overcome tumor resistance to methotrexate, which loses its activity after it is polyglutamated.
| Identifier | MLC-T-ONC-002674 |
|---|---|
| Field | Oncology and biomedicine |
| Abbreviation | 10-EdAM |
| References | NCI Dictionary of Cancer Terms; National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-002674",
"term": "edatrexate",
"field": "Oncology and biomedicine",
"definitions": [
"An anticancer drug that belongs to a family of drugs called antimetabolites.",
"A polyglutamatable folate antagonist analogue of methotrexate with antineoplastic activity. Edatrexate inhibits dihydrofolate reductase, thereby increasing cellular levels of polyglutamates, inhibiting thymidylate synthase and glycinamide ribonucleotide formyl transferase, impairing synthesis of purine nucleotides and amino acids, and resulting in tumor cell death. Edatrexate may overcome tumor resistance to methotrexate, which loses its activity after it is polyglutamated."
],
"abbreviation": "10-EdAM",
"references": [
"NCI Dictionary of Cancer Terms",
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/edatrexate/"
}
Record 6,372 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.